European Commission grants conditional marketing authorisation to remdesivir (Veklury) for treatment of COVID-19
The license is for the treatment of COVID-19 in adults and adolescents from 12 years of age with pneumonia who require supplemental oxygen and follows the CHMP recommendation from 25 June 2020.
Source:
European Medicines Agency
SPS commentary:
The Department for Health and Social Care have issued an interim clinical commissioning policy to define routine access to the remdesivir in the treatment of COVID-19 across the UK.